Get the Stockscreener App
5.77
1.20%
-0.07
Pre-market:
5.75
-0.02
-0.35%
Clene Inc stock is traded at $5.77, with a volume of 64,298.
It is down -1.20% in the last 24 hours and down -19.19% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$5.84
Open:
$5.99
24h Volume:
64,298
Relative Volume:
0.14
Market Cap:
$73.73M
Revenue:
$134.00K
Net Income/Loss:
$-33.51M
P/E Ratio:
-1.799
EPS:
-3.2074
Net Cash Flow:
$-18.15M
1W Performance:
+8.26%
1M Performance:
-19.19%
6M Performance:
-7.53%
1Y Performance:
+40.73%
1-Day Range:
$5.75
$6.06
1-Week Range:
$5.25
$6.06
52-Week Range:
$3.25
$13.50
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
5.77 | 73.73M | 134.00K | -33.51M | -18.15M | -3.2074 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Clene (CLNN) Chief Science Officer receives 45,000-share stock option grant - Stock Titan
Clene (CLNN) CEO receives 65,000 stock options at $5.53 exercise price - Stock Titan
Clene (CLNN) grants CFO 15,000 stock options at $5.53 strike - Stock Titan
Clene Inc. (CLNN) Gains 5.6% as Shares Approach Key ResistanceFactor Valuation - newsline.com
TruckMountForums acquires Bane-Clene Corporation, uniting two fam - The National Law Review
Clene (CLNN) may find a bottom soon, here's why you should buy the stock now - MSN
Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
CLNN Technical Analysis & Stock Price Forecast - Intellectia AI
Clene Inc. (CLNN) Shares Slide 2.24% as Stock Tests Key Support LevelsThrowback Trade - thelegaladvocate.com
CLNN stock falls after Roth labels accelerated approval for ALS drug a 'long shot' - MSN
CLNN stock rises 8% – here’s what the FDA update means for Clene’s ALS treatment - MSN
Clene Inc. Files Form 8-K with SEC Detailing Company Information and Common Stock Listing on NASDAQ - Minichart
Clene extends note maturity and amends stock plan following annual meeting - Investing.com
Clene Extends 2025 Convertible Notes to 2027, Defers $150,000 Monthly Payments - TradingView
Clene (NASDAQ: CLNN) extends convertible note maturity and adds 1M plan shares - Stock Titan
Clene (NASDAQ: CLNN) director granted 3,564 stock options at $6.81 exercise price - Stock Titan
Clene Inc. (NASDAQ: CLNN) director receives 3,658 stock options at $6.81 strike - Stock Titan
Clene (NASDAQ: CLNN) director awarded 4,361 stock options at $6.81 strike - Stock Titan
Clene Inc. (CLNN) director granted 5,159 stock options as equity compensation - Stock Titan
Clene (CLNN) director granted 4,291-share stock option package - Stock Titan
[Form 4] Clene Inc. Insider Trading Activity - Stock Titan
Clene (NASDAQ: CLNN) director Jonathon Gay receives 3,728 stock options at $6.81 - Stock Titan
Clene (CLNN) awards director two stock option grants at $6.81 - Stock Titan
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year? - Yahoo Finance
Clene Inc. (CLNN) reports Q1 loss, misses revenue estimates - MSN
CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’ - Stocktwits
Clene (CLNN) Gets a Buy from JonesTrading - The Globe and Mail
Is Clene (CLNN) Overvalued After Q1 2026? EPS -$0.69 Misses Est. - GuruFocus
JonesTrading Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
A Quick Look at Today's Ratings for Clene(CLNN.US), With a Forecast Between $30 to $50 - Moomoo
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Chidozie Ugwumba reports 9.7% stake in Clene Inc. (CLNN) - Stock Titan
Clene Inc. 2026 Q1 Financial Results, Risk Factors, and Forward-Looking Statements – Quarterly Report Highlights - Minichart
Clene (CLNN) Receives Positive Analyst Rating and Funding Outloo - GuruFocus
Clene Inc. (NASDAQ: CLNN) insider reports 1.83M shares, 13% - Stock Titan
Clene (CLNN) Reports Q1 Revenue and Progress on ALS Treatment - GuruFocus
Chidozie Ugwumba reports 1.92M Clene shares (NASDAQ: CLNN) 14.8% - Stock Titan
Clene Releases Q1 2026 Financial Results - AlphaStreet
Clene Reports Q1 2026 Loss Amid Positive Regulatory News for CNM-Au8 - GuruFocus
Clene Inc. Reports Q1 2026 Financial Results and Advances CNM-Au8 for ALS FDA Approval - Minichart
Clene 3Q Rev $15,000 >CLNN - Moomoo
Clene Expects to Submit NDA for CNM-Au8 Under the Accelerated Approval Pathway in 3Q >CLNN - Moomoo
Clene 3Q Loss/Shr 69c >CLNN - Moomoo
Clene Sees Operating Runway Into 4Q of 2026 - Moomoo
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clene Inc Stock (CLNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ugwumba Chidozie | 10% Owner |
May 11 '26 |
Sale |
6.75 |
22,177 |
149,695 |
176,713 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):